+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Minimal residual disease (MRD) - Pipeline Insight, 2020

  • ID: 5215148
  • Clinical Trials
  • December 2020
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Bellicum Pharmaceuticals
  • Janssen
  • Novartis
  • Synimmune
This “Minimal residual disease (MRD) - Pipeline Insight, 2020,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Minimal residual disease (MRD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Minimal residual disease (MRD) Understanding

Minimal residual disease (MRD): Overview

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after cancer treatment. These cells do not cause any physical signs or symptoms. After cancer treatment, any remaining cancer cells in the body can become active and start to multiply, causing a relapse of the disease. Minimal residual disease may be present after treatment because not all of the cancer cells responded to the therapy, or because the cancer cells became resistant to the medications used. Detecting MRD may indicate that the treatment was not completely effective or that the treatment was incomplete. An MRD positive test result or negative result provide doctors an idea about the risk of relapse in cancer patients. MRD testing is mainly used in blood cancers (leukemia, lymphoma and myeloma), but is being studied in other cancers also.

Diagnosis

There are different criteria for when to test for MRD, based on factors specific to the patient's disease. Patients may be tested after the final cycle of combination therapy, after bone marrow transplantation, during treatment, after one year on maintenance therapy, or at regular intervals after treatment is completed. The more sensitive a test is, the more effective it is at finding a small amount of cancer cells among the many healthy cells. The most widely used tests to measure MRD are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS).

Minimal residual disease (MRD) Emerging Drugs Chapters

This segment of the Minimal residual disease (MRD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Minimal residual disease (MRD) Emerging Drugs

FLYSYN: Synimmune

FLYSYN is a monospecific antibody for the treatment of acute myeloid leukemia (AML) patients at a stage of minimum residual disease (MRD). FLYSYN is currently evaluated in a Phase I/II study. FLYSYN contains a genetic optimization of its Fc-part resulting in optimized binding to cells expressing the Fc receptor, particularly Natural Killer (NK) cells, and thus substantially improved antibody dependent cell-mediated cytotoxicity (ADCC).

BPX-501: Bellicum Pharmaceuticals

BPX-501 (Rivogenlecleucel) is an allogeneic product consisting of T cells, modified to express the inducible caspase-9 (iC9) safety switch. The treatment is currently under Phase I study in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.

Minimal residual disease (MRD): Therapeutic Assessment

This segment of the report provides insights about the different Minimal residual disease (MRD) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Minimal residual disease (MRD)

There are approx. 8+ key companies which are developing the therapies for Minimal residual disease (MRD).

Phases

This report covers around 8+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Minimal residual disease (MRD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Minimal residual disease (MRD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Minimal residual disease (MRD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Minimal residual disease (MRD) drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Minimal residual disease (MRD) R&D. The therapies under development are focused on novel approaches to treat/improve Minimal residual disease (MRD).
  • In August 2020, Adaptive Biotechnologies announces that US FDA cleared the clonoSEQ assay to detect and monitor minimal residual disease (MRD) in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL).
Minimal residual disease (MRD) Report Insights
  • Minimal residual disease (MRD) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Minimal residual disease (MRD) Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Minimal residual disease (MRD) drugs?
  • How many Minimal residual disease (MRD) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Minimal residual disease (MRD)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Minimal residual disease (MRD) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Minimal residual disease (MRD) and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Amgen
  • Bellicum Pharmaceuticals
  • Synimmune
  • Novartis
  • AstraZeneca
  • Janssen
  • Shanghai iCELL Biotechnology
Key Products
  • Blinatumomab
  • BPX-501
  • FLYSYN
  • Nilotinib
  • Durvalumab
  • Daratumumab
  • Haploid allogeneic NK cell therapy
  • CTL019

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Bellicum Pharmaceuticals
  • Janssen
  • Novartis
  • Synimmune
Introduction

Executive Summary

Minimal residual disease (MRD): Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Minimal residual disease (MRD)- Analytical Perspective

In-depth Commercial Assessment
  • Minimal residual disease (MRD) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Minimal residual disease (MRD) Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Durvalumab: AstraZeneca
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
CTL019 : Novartis
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
FLYSYN: Synimmune
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Minimal residual disease (MRD) Key Companies

Minimal residual disease (MRD) Key Products

Minimal residual disease (MRD)- Unmet Needs

Minimal residual disease (MRD)- Market Drivers and Barriers

Minimal residual disease (MRD)- Future Perspectives and Conclusion

Minimal residual disease (MRD) Analyst Views

Minimal residual disease (MRD) Key Companies

Appendix

List of Tables
Table 1 Total Products for Minimal residual disease (MRD)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Minimal residual disease (MRD)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Amgen
  • Bellicum Pharmaceuticals
  • Synimmune
  • Novartis
  • AstraZeneca
  • Janssen
  • Shanghai iCELL Biotechnology
Note: Product cover images may vary from those shown
Adroll
adroll